A gene expression signature of TREM2hi macrophages and γδ T cells predicts immunotherapy response
Most cancer patients do not respond to immune checkpoint therapies and the availability of predictive biomarkers is limited. Here the authors propose a signature enriched for genes of TREM2hi macrophages and γδ T cells to predict response to immunotherapy.
Main Authors: | Donghai Xiong, Yian Wang, Ming You |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2020-10-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-020-18546-x |
Similar Items
-
γδ T Cell Immunotherapy—A Review
by: Hirohito Kobayashi, et al.
Published: (2015-02-01) -
γδ T Cells: The Ideal Tool for Cancer Immunotherapy
by: Mahboubeh Yazdanifar, et al.
Published: (2020-05-01) -
Current Advances in γδ T Cell-Based Tumor Immunotherapy
by: Elena Lo Presti, et al.
Published: (2017-10-01) -
Cancer immunotherapy using γδT cells: dealing with diversity
by: Wouter eScheper, et al.
Published: (2014-11-01) -
Γδ T Cell-Based Immunotherapy in Melanoma: State of the Art
by: F. Toia, et al.
Published: (2019-01-01)